# A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

> **NCT04469062** · PHASE3 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Mirikizumab IV
- **DRUG:** Mirikizumab SC
- **DRUG:** Vedolizumab IV
- **DRUG:** Placebo IV
- **DRUG:** Placebo SC

## Key facts

- **NCT ID:** NCT04469062
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-20
- **Primary completion:** 2024-03-13
- **Final completion:** 2024-06-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial was terminated secondary to a business decision, the original scientific question rendered moot by the external scientific community.
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04469062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04469062, "A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04469062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*